Taisho Pharmaceutical Co., Ltd.
https://www.taisho.co.jp/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Taisho Pharmaceutical Co., Ltd.
‘Skinny Label’ Case Gives Brands A ‘Blueprint’ To Alter Use Codes In Patent Litigation
Federal Circuit ruling in GSK v. Teva shows brands can broaden a use code to include other patented indications years into litigation, AAM attorney says. The case is ‘scarier’ for biosimilar makers since they must market their products, Teva lawyer notes.
Keeping Track: US FDA Clears Opioid Seglentis And Anti-Opioid Zimhi; CRLs For Revance, United; Delay For UCB
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Deal Watch: Appili Gets AiPharma’s Help In Advancing COVID-19 Therapy
Appili brings in AiPharma to help with US/Canadian development of Fujifilm’s potential COVID-19 preventative/therapeutic. Other recent tie-ups include CinFina/Janssen, Bone/Impant, Bayer/Gubra, Novartis/Theragnostics, Grifols/Biotest and more.
Hikma Buys Injectables Specialist Custopharm In $400m+ Deal
Hikma has agreed to acquire US sterile injectables specialist Custopharm in a deal that includes a $375m upfront purchase price and a further $50m in milestone payments. The transaction is set to bolster Hikma’s near-$1bn injectables business that currently accounts for around two-fifths of turnover.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
- Transdermal
-
Drug Delivery
- Other Names / Subsidiaries
-
- Hoepharma Holdings Sdn. Bhd.
- Taisho Toyama Pharmaceutical Co., Ltd.
- TOKUHON Corporation
- UPSA SAS